Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bryostatin-I—An Antineoplastic Treasure from the Deep?

9 Jul 2002

Abstract excerpt

No Abstract Available Commentary to: Title: Phase I Study of Prolonged Infusion Bryostatin-1 in Patients with Advanced Malignancies Authors: John L. Marshall, Neelesh Bangalore, Dorraya El-Ashry, Yair Fuxman, Michael Johnson, Brian Norris, Michael Oberst, Elizabeth Ness, Slawomir Wojtowicz-Praga, Pankaj Bhargava, Naiyer Rizvi, Said Baidas and Michael J. Hawkins Page Numbers: 409-416

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Multiple Myeloma Research and Treatments
Share to Proteoglycans and glycosaminoglycans research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12432258
DOI: 10.4161/cbt.1.4.20

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Bryostatin-I—An Antineoplastic Treasure from the Deep?PMID 12432258Read ↗

Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical ApplicationsSemantic proximity Read ↗

The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell lineSemantic proximity Read ↗

Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells.Semantic proximity Read ↗

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapySemantic proximity Read ↗

A New Frontier in the Treatment of Cancer: NK-1 Receptor AntagonistsSemantic proximity Read ↗

The oncostatin M signalling pathway: reversing the neoplastic phenotype?Semantic proximity Read ↗

Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.Semantic proximity Read ↗

GBM radiosensitizers: dead in the water…or just the beginning?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.